nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—Pain in jaw—Saquinavir—acquired immunodeficiency syndrome	0.0257	0.0326	CcSEcCtD
Phentolamine—Blood pressure increased—Nevirapine—acquired immunodeficiency syndrome	0.0133	0.0169	CcSEcCtD
Phentolamine—Abdominal pain upper—Didanosine—acquired immunodeficiency syndrome	0.00982	0.0125	CcSEcCtD
Phentolamine—Acute coronary syndrome—Amprenavir—acquired immunodeficiency syndrome	0.00896	0.0114	CcSEcCtD
Phentolamine—Myocardial infarction—Amprenavir—acquired immunodeficiency syndrome	0.00891	0.0113	CcSEcCtD
Phentolamine—Abdominal pain upper—Nelfinavir—acquired immunodeficiency syndrome	0.00855	0.0109	CcSEcCtD
Phentolamine—Abdominal pain upper—Abacavir—acquired immunodeficiency syndrome	0.0084	0.0107	CcSEcCtD
Phentolamine—Cardiac disorder—Amprenavir—acquired immunodeficiency syndrome	0.00757	0.00963	CcSEcCtD
Phentolamine—NISCH—blood—acquired immunodeficiency syndrome	0.00718	0.0463	CbGeAlD
Phentolamine—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00714	0.046	CbGeAlD
Phentolamine—Acute coronary syndrome—Abacavir—acquired immunodeficiency syndrome	0.00698	0.00888	CcSEcCtD
Phentolamine—NISCH—bone marrow—acquired immunodeficiency syndrome	0.00695	0.0448	CbGeAlD
Phentolamine—Myocardial infarction—Abacavir—acquired immunodeficiency syndrome	0.00694	0.00883	CcSEcCtD
Phentolamine—NISCH—spinal cord—acquired immunodeficiency syndrome	0.00692	0.0446	CbGeAlD
Phentolamine—NISCH—vagina—acquired immunodeficiency syndrome	0.00665	0.0429	CbGeAlD
Phentolamine—Angina pectoris—Indinavir—acquired immunodeficiency syndrome	0.00635	0.00808	CcSEcCtD
Phentolamine—NISCH—lung—acquired immunodeficiency syndrome	0.00629	0.0406	CbGeAlD
Phentolamine—Orthostatic hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00623	0.00792	CcSEcCtD
Phentolamine—Angiopathy—Nelfinavir—acquired immunodeficiency syndrome	0.00587	0.00747	CcSEcCtD
Phentolamine—Orthostatic hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00576	0.00732	CcSEcCtD
Phentolamine—Acute coronary syndrome—Indinavir—acquired immunodeficiency syndrome	0.00573	0.00729	CcSEcCtD
Phentolamine—Myocardial infarction—Indinavir—acquired immunodeficiency syndrome	0.0057	0.00725	CcSEcCtD
Phentolamine—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00568	0.00723	CcSEcCtD
Phentolamine—Abdominal pain upper—Saquinavir—acquired immunodeficiency syndrome	0.00554	0.00705	CcSEcCtD
Phentolamine—Abdominal pain upper—Lamivudine—acquired immunodeficiency syndrome	0.00529	0.00673	CcSEcCtD
Phentolamine—Cardiac disorder—Zidovudine—acquired immunodeficiency syndrome	0.00521	0.00662	CcSEcCtD
Phentolamine—Paraesthesia—Amprenavir—acquired immunodeficiency syndrome	0.0052	0.00662	CcSEcCtD
Phentolamine—Mediastinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00506	0.00643	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.005	0.00636	CcSEcCtD
Phentolamine—ADRA1B—nervous system—acquired immunodeficiency syndrome	0.00497	0.0321	CbGeAlD
Phentolamine—ADRA1D—nervous system—acquired immunodeficiency syndrome	0.00486	0.0314	CbGeAlD
Phentolamine—Flushing—Indinavir—acquired immunodeficiency syndrome	0.00484	0.00616	CcSEcCtD
Phentolamine—Bradycardia—Delavirdine—acquired immunodeficiency syndrome	0.0048	0.00611	CcSEcCtD
Phentolamine—Acute coronary syndrome—Ritonavir—acquired immunodeficiency syndrome	0.00479	0.00609	CcSEcCtD
Phentolamine—ADRA1B—central nervous system—acquired immunodeficiency syndrome	0.00479	0.0309	CbGeAlD
Phentolamine—Myocardial infarction—Ritonavir—acquired immunodeficiency syndrome	0.00476	0.00606	CcSEcCtD
Phentolamine—Paraesthesia—Didanosine—acquired immunodeficiency syndrome	0.00474	0.00603	CcSEcCtD
Phentolamine—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.00474	0.00603	CcSEcCtD
Phentolamine—ADRA1D—central nervous system—acquired immunodeficiency syndrome	0.00468	0.0302	CbGeAlD
Phentolamine—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00466	0.00592	CcSEcCtD
Phentolamine—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.00458	0.00583	CcSEcCtD
Phentolamine—Cardiac disorder—Efavirenz—acquired immunodeficiency syndrome	0.00458	0.00582	CcSEcCtD
Phentolamine—Flushing—Efavirenz—acquired immunodeficiency syndrome	0.00458	0.00582	CcSEcCtD
Phentolamine—Pain—Didanosine—acquired immunodeficiency syndrome	0.00452	0.00575	CcSEcCtD
Phentolamine—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.0045	0.00572	CcSEcCtD
Phentolamine—Angiopathy—Efavirenz—acquired immunodeficiency syndrome	0.00447	0.00569	CcSEcCtD
Phentolamine—NISCH—brain—acquired immunodeficiency syndrome	0.00445	0.0287	CbGeAlD
Phentolamine—Mediastinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00444	0.00565	CcSEcCtD
Phentolamine—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00443	0.00564	CcSEcCtD
Phentolamine—Arrhythmia—Efavirenz—acquired immunodeficiency syndrome	0.0044	0.0056	CcSEcCtD
Phentolamine—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.00432	0.00549	CcSEcCtD
Phentolamine—NISCH—lymph node—acquired immunodeficiency syndrome	0.0043	0.0277	CbGeAlD
Phentolamine—Paraesthesia—Nevirapine—acquired immunodeficiency syndrome	0.00427	0.00542	CcSEcCtD
Phentolamine—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.00422	0.00537	CcSEcCtD
Phentolamine—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.00418	0.00531	CcSEcCtD
Phentolamine—SIGMAR1—blood—acquired immunodeficiency syndrome	0.00418	0.0269	CbGeAlD
Phentolamine—Chest pain—Zidovudine—acquired immunodeficiency syndrome	0.00416	0.00529	CcSEcCtD
Phentolamine—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.00416	0.00529	CcSEcCtD
Phentolamine—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.00413	0.00525	CcSEcCtD
Phentolamine—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00412	0.00524	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.0041	0.00522	CcSEcCtD
Phentolamine—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.0041	0.00521	CcSEcCtD
Phentolamine—Pain—Nevirapine—acquired immunodeficiency syndrome	0.00406	0.00517	CcSEcCtD
Phentolamine—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.00406	0.00516	CcSEcCtD
Phentolamine—Flushing—Ritonavir—acquired immunodeficiency syndrome	0.00405	0.00515	CcSEcCtD
Phentolamine—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.00405	0.00515	CcSEcCtD
Phentolamine—SIGMAR1—bone marrow—acquired immunodeficiency syndrome	0.00404	0.026	CbGeAlD
Phentolamine—SIGMAR1—spinal cord—acquired immunodeficiency syndrome	0.00402	0.0259	CbGeAlD
Phentolamine—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00397	0.00505	CcSEcCtD
Phentolamine—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00396	0.00504	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.00396	0.00504	CcSEcCtD
Phentolamine—Angiopathy—Ritonavir—acquired immunodeficiency syndrome	0.00396	0.00503	CcSEcCtD
Phentolamine—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.00393	0.005	CcSEcCtD
Phentolamine—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00393	0.005	CcSEcCtD
Phentolamine—Pain—Stavudine—acquired immunodeficiency syndrome	0.00392	0.00499	CcSEcCtD
Phentolamine—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00391	0.00497	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.0039	0.00496	CcSEcCtD
Phentolamine—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.0039	0.00496	CcSEcCtD
Phentolamine—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.00388	0.00494	CcSEcCtD
Phentolamine—SIGMAR1—vagina—acquired immunodeficiency syndrome	0.00387	0.025	CbGeAlD
Phentolamine—Chest pain—Indinavir—acquired immunodeficiency syndrome	0.00387	0.00492	CcSEcCtD
Phentolamine—Pain—Abacavir—acquired immunodeficiency syndrome	0.00386	0.00491	CcSEcCtD
Phentolamine—Angiopathy—Saquinavir—acquired immunodeficiency syndrome	0.00381	0.00484	CcSEcCtD
Phentolamine—ADRA1B—brain—acquired immunodeficiency syndrome	0.0038	0.0245	CbGeAlD
Phentolamine—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.00379	0.00482	CcSEcCtD
Phentolamine—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00378	0.00481	CcSEcCtD
Phentolamine—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00376	0.00478	CcSEcCtD
Phentolamine—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00375	0.00478	CcSEcCtD
Phentolamine—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.00375	0.00477	CcSEcCtD
Phentolamine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00374	0.00475	CcSEcCtD
Phentolamine—ADRA1D—brain—acquired immunodeficiency syndrome	0.00372	0.024	CbGeAlD
Phentolamine—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.00371	0.00471	CcSEcCtD
Phentolamine—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.00369	0.0047	CcSEcCtD
Phentolamine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00368	0.00469	CcSEcCtD
Phentolamine—SIGMAR1—lung—acquired immunodeficiency syndrome	0.00366	0.0236	CbGeAlD
Phentolamine—ADRA1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00366	0.0236	CbGeAlD
Phentolamine—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.00365	0.00465	CcSEcCtD
Phentolamine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00364	0.00463	CcSEcCtD
Phentolamine—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00364	0.00462	CcSEcCtD
Phentolamine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00363	0.00462	CcSEcCtD
Phentolamine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00363	0.00461	CcSEcCtD
Phentolamine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00361	0.0046	CcSEcCtD
Phentolamine—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00361	0.00459	CcSEcCtD
Phentolamine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00358	0.00455	CcSEcCtD
Phentolamine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00357	0.00454	CcSEcCtD
Phentolamine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00355	0.00451	CcSEcCtD
Phentolamine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.0035	0.00445	CcSEcCtD
Phentolamine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00344	0.00438	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.00344	0.00438	CcSEcCtD
Phentolamine—ADRA1A—blood—acquired immunodeficiency syndrome	0.00344	0.0222	CbGeAlD
Phentolamine—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00343	0.00437	CcSEcCtD
Phentolamine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00342	0.00435	CcSEcCtD
Phentolamine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00341	0.00434	CcSEcCtD
Phentolamine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00341	0.00433	CcSEcCtD
Phentolamine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00336	0.00427	CcSEcCtD
Phentolamine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00336	0.00427	CcSEcCtD
Phentolamine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00333	0.00423	CcSEcCtD
Phentolamine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00331	0.00421	CcSEcCtD
Phentolamine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.0033	0.0042	CcSEcCtD
Phentolamine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.00329	0.00419	CcSEcCtD
Phentolamine—ADRA2C—blood—acquired immunodeficiency syndrome	0.00328	0.0211	CbGeAlD
Phentolamine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00328	0.00417	CcSEcCtD
Phentolamine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00327	0.00416	CcSEcCtD
Phentolamine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00326	0.00415	CcSEcCtD
Phentolamine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00325	0.00414	CcSEcCtD
Phentolamine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00325	0.00413	CcSEcCtD
Phentolamine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00324	0.00413	CcSEcCtD
Phentolamine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00324	0.00412	CcSEcCtD
Phentolamine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.00323	0.00411	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.0032	0.00407	CcSEcCtD
Phentolamine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.0032	0.00407	CcSEcCtD
Phentolamine—Pain—Indinavir—acquired immunodeficiency syndrome	0.00317	0.00403	CcSEcCtD
Phentolamine—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.00316	0.0204	CbGeAlD
Phentolamine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00316	0.00401	CcSEcCtD
Phentolamine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00315	0.00401	CcSEcCtD
Phentolamine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00315	0.004	CcSEcCtD
Phentolamine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00315	0.004	CcSEcCtD
Phentolamine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00314	0.00399	CcSEcCtD
Phentolamine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00314	0.00399	CcSEcCtD
Phentolamine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00313	0.00398	CcSEcCtD
Phentolamine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00311	0.00396	CcSEcCtD
Phentolamine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.00309	0.00393	CcSEcCtD
Phentolamine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00304	0.00387	CcSEcCtD
Phentolamine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00304	0.00387	CcSEcCtD
Phentolamine—ADRA2C—vagina—acquired immunodeficiency syndrome	0.00304	0.0196	CbGeAlD
Phentolamine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00303	0.00386	CcSEcCtD
Phentolamine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.00303	0.00386	CcSEcCtD
Phentolamine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00302	0.00385	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00302	0.00385	CcSEcCtD
Phentolamine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00302	0.00384	CcSEcCtD
Phentolamine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00301	0.00383	CcSEcCtD
Phentolamine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.003	0.00381	CcSEcCtD
Phentolamine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00299	0.0038	CcSEcCtD
Phentolamine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00298	0.00378	CcSEcCtD
Phentolamine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.00297	0.00378	CcSEcCtD
Phentolamine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00293	0.00373	CcSEcCtD
Phentolamine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.00293	0.00372	CcSEcCtD
Phentolamine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00292	0.00372	CcSEcCtD
Phentolamine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00292	0.00371	CcSEcCtD
Phentolamine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.0029	0.00368	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.00289	0.00368	CcSEcCtD
Phentolamine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00288	0.00367	CcSEcCtD
Phentolamine—ADRA2C—lung—acquired immunodeficiency syndrome	0.00287	0.0185	CbGeAlD
Phentolamine—Headache—Stavudine—acquired immunodeficiency syndrome	0.00287	0.00365	CcSEcCtD
Phentolamine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00287	0.00365	CcSEcCtD
Phentolamine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.00287	0.00364	CcSEcCtD
Phentolamine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.00286	0.00364	CcSEcCtD
Phentolamine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.00286	0.00364	CcSEcCtD
Phentolamine—Headache—Abacavir—acquired immunodeficiency syndrome	0.00283	0.0036	CcSEcCtD
Phentolamine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00282	0.00359	CcSEcCtD
Phentolamine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00282	0.00359	CcSEcCtD
Phentolamine—ADRA1A—nervous system—acquired immunodeficiency syndrome	0.00279	0.018	CbGeAlD
Phentolamine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.00279	0.00355	CcSEcCtD
Phentolamine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00279	0.00354	CcSEcCtD
Phentolamine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00278	0.00354	CcSEcCtD
Phentolamine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.00277	0.00352	CcSEcCtD
Phentolamine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00274	0.00349	CcSEcCtD
Phentolamine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.00273	0.00348	CcSEcCtD
Phentolamine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00273	0.00347	CcSEcCtD
Phentolamine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00272	0.00346	CcSEcCtD
Phentolamine—ADRA1A—central nervous system—acquired immunodeficiency syndrome	0.00269	0.0173	CbGeAlD
Phentolamine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00268	0.00341	CcSEcCtD
Phentolamine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00268	0.00341	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00268	0.0034	CcSEcCtD
Phentolamine—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.00266	0.0172	CbGeAlD
Phentolamine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.00266	0.00338	CcSEcCtD
Phentolamine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.00266	0.00338	CcSEcCtD
Phentolamine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.00265	0.00337	CcSEcCtD
Phentolamine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00265	0.00337	CcSEcCtD
Phentolamine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.00264	0.00335	CcSEcCtD
Phentolamine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.00262	0.00334	CcSEcCtD
Phentolamine—ADRA2A—blood—acquired immunodeficiency syndrome	0.00262	0.0169	CbGeAlD
Phentolamine—SIGMAR1—brain—acquired immunodeficiency syndrome	0.00259	0.0167	CbGeAlD
Phentolamine—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.00258	0.00328	CcSEcCtD
Phentolamine—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.00256	0.0165	CbGeAlD
Phentolamine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.00256	0.00325	CcSEcCtD
Phentolamine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.00255	0.00324	CcSEcCtD
Phentolamine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00254	0.00323	CcSEcCtD
Phentolamine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00253	0.00322	CcSEcCtD
Phentolamine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.00253	0.00322	CcSEcCtD
Phentolamine—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.00252	0.0163	CbGeAlD
Phentolamine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00251	0.0032	CcSEcCtD
Phentolamine—SIGMAR1—lymph node—acquired immunodeficiency syndrome	0.0025	0.0161	CbGeAlD
Phentolamine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.0025	0.00318	CcSEcCtD
Phentolamine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.00248	0.00315	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00246	0.00312	CcSEcCtD
Phentolamine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00245	0.00312	CcSEcCtD
Phentolamine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00245	0.00312	CcSEcCtD
Phentolamine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00244	0.0031	CcSEcCtD
Phentolamine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00243	0.00309	CcSEcCtD
Phentolamine—ADRA2A—vagina—acquired immunodeficiency syndrome	0.00243	0.0156	CbGeAlD
Phentolamine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.0024	0.00306	CcSEcCtD
Phentolamine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.0024	0.00305	CcSEcCtD
Phentolamine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.00237	0.00302	CcSEcCtD
Phentolamine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00237	0.00301	CcSEcCtD
Phentolamine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.00236	0.003	CcSEcCtD
Phentolamine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00236	0.003	CcSEcCtD
Phentolamine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.00233	0.00296	CcSEcCtD
Phentolamine—Headache—Indinavir—acquired immunodeficiency syndrome	0.00232	0.00295	CcSEcCtD
Phentolamine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00232	0.00295	CcSEcCtD
Phentolamine—ADRA2A—lung—acquired immunodeficiency syndrome	0.00229	0.0148	CbGeAlD
Phentolamine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00229	0.00292	CcSEcCtD
Phentolamine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00225	0.00286	CcSEcCtD
Phentolamine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00223	0.00283	CcSEcCtD
Phentolamine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.00222	0.00283	CcSEcCtD
Phentolamine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.00222	0.00282	CcSEcCtD
Phentolamine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.0022	0.0028	CcSEcCtD
Phentolamine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00219	0.00279	CcSEcCtD
Phentolamine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.00219	0.00279	CcSEcCtD
Phentolamine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.00214	0.00272	CcSEcCtD
Phentolamine—ADRA1A—brain—acquired immunodeficiency syndrome	0.00214	0.0138	CbGeAlD
Phentolamine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00213	0.00271	CcSEcCtD
Phentolamine—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.00212	0.0137	CbGeAlD
Phentolamine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.00212	0.0027	CcSEcCtD
Phentolamine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.00211	0.00268	CcSEcCtD
Phentolamine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.0021	0.00267	CcSEcCtD
Phentolamine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00208	0.00265	CcSEcCtD
Phentolamine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.00205	0.00261	CcSEcCtD
Phentolamine—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.00204	0.0132	CbGeAlD
Phentolamine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00204	0.0026	CcSEcCtD
Phentolamine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00204	0.0026	CcSEcCtD
Phentolamine—ADRA2C—brain—acquired immunodeficiency syndrome	0.00203	0.0131	CbGeAlD
Phentolamine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00201	0.00256	CcSEcCtD
Phentolamine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00199	0.00253	CcSEcCtD
Phentolamine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00197	0.00251	CcSEcCtD
Phentolamine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00197	0.00251	CcSEcCtD
Phentolamine—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.00197	0.0127	CbGeAlD
Phentolamine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.00195	0.00248	CcSEcCtD
Phentolamine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00194	0.00247	CcSEcCtD
Phentolamine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.0019	0.00241	CcSEcCtD
Phentolamine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00188	0.00239	CcSEcCtD
Phentolamine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00187	0.00238	CcSEcCtD
Phentolamine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00184	0.00234	CcSEcCtD
Phentolamine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00181	0.0023	CcSEcCtD
Phentolamine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00178	0.00227	CcSEcCtD
Phentolamine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00177	0.00225	CcSEcCtD
Phentolamine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00169	0.00215	CcSEcCtD
Phentolamine—ADRA2A—brain—acquired immunodeficiency syndrome	0.00162	0.0105	CbGeAlD
Phentolamine—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.00157	0.0101	CbGeAlD
Phentolamine—ADRA1D—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000182	0.00311	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000182	0.00311	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000182	0.0031	CbGpPWpGaD
Phentolamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00018	0.00307	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000179	0.00305	CbGpPWpGaD
Phentolamine—ADRA2A—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000178	0.00303	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000177	0.00302	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—TAT—acquired immunodeficiency syndrome	0.000177	0.00301	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000174	0.00297	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000174	0.00297	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000174	0.00296	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000171	0.00292	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000171	0.00292	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000171	0.00292	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00017	0.0029	CbGpPWpGaD
Phentolamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000168	0.00286	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000167	0.00285	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000166	0.00283	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000166	0.00283	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000165	0.00281	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000163	0.00278	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000162	0.00276	CbGpPWpGaD
Phentolamine—ADRA2A—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00016	0.00273	CbGpPWpGaD
Phentolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00016	0.00272	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000159	0.00272	CbGpPWpGaD
Phentolamine—ADRA2B—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000158	0.00269	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000157	0.00268	CbGpPWpGaD
Phentolamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000157	0.00267	CbGpPWpGaD
Phentolamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000154	0.00263	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000154	0.00262	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000152	0.00259	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000152	0.00259	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000152	0.00259	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000151	0.00258	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00015	0.00256	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00015	0.00256	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000149	0.00254	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000149	0.00253	CbGpPWpGaD
Phentolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000148	0.00253	CbGpPWpGaD
Phentolamine—ADRA2C—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000147	0.00251	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000145	0.00247	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—TAT—acquired immunodeficiency syndrome	0.000143	0.00245	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000142	0.00242	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000141	0.00241	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000141	0.00241	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000141	0.00241	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000141	0.00241	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000138	0.00235	CbGpPWpGaD
Phentolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000137	0.00233	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000135	0.00229	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000134	0.00229	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000132	0.00226	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00013	0.00222	CbGpPWpGaD
Phentolamine—ADRA2B—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000128	0.00218	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000128	0.00218	CbGpPWpGaD
Phentolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000127	0.00217	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000125	0.00213	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000125	0.00213	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000125	0.00212	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000124	0.00211	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000122	0.00208	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000121	0.00206	CbGpPWpGaD
Phentolamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.00012	0.00204	CbGpPWpGaD
Phentolamine—ADRA2C—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.00012	0.00204	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000119	0.00203	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000119	0.00203	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000119	0.00203	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000117	0.002	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000117	0.00199	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000117	0.00199	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000117	0.00199	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000116	0.00197	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000113	0.00192	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000112	0.00192	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000112	0.00191	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000108	0.00184	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000107	0.00183	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000107	0.00183	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000107	0.00183	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000106	0.00181	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000106	0.00181	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000105	0.00179	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000105	0.00179	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000105	0.00179	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000105	0.00178	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000104	0.00178	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000103	0.00176	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000103	0.00175	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000102	0.00173	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.0001	0.00171	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.0001	0.00171	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.88e-05	0.00168	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.88e-05	0.00168	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.83e-05	0.00168	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.83e-05	0.00168	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.72e-05	0.00166	CbGpPWpGaD
Phentolamine—ADRA2A—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	9.71e-05	0.00166	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.68e-05	0.00165	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.68e-05	0.00165	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.68e-05	0.00165	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9.56e-05	0.00163	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9.56e-05	0.00163	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.5e-05	0.00162	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—CSF2—acquired immunodeficiency syndrome	9.47e-05	0.00161	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.35e-05	0.00159	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.18e-05	0.00157	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.14e-05	0.00156	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.08e-05	0.00155	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.94e-05	0.00152	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.93e-05	0.00152	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.93e-05	0.00152	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.87e-05	0.00151	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.79e-05	0.0015	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.79e-05	0.0015	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.78e-05	0.0015	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.78e-05	0.0015	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.74e-05	0.00149	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.59e-05	0.00147	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.59e-05	0.00147	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.53e-05	0.00145	CbGpPWpGaD
Phentolamine—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	8.52e-05	0.00145	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.49e-05	0.00145	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.3e-05	0.00142	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.15e-05	0.00139	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.15e-05	0.00139	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	8.13e-05	0.00139	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.05e-05	0.00137	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.01e-05	0.00137	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.99e-05	0.00136	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.99e-05	0.00136	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.99e-05	0.00136	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.94e-05	0.00135	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.93e-05	0.00135	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.89e-05	0.00134	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.8e-05	0.00133	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.8e-05	0.00133	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.71e-05	0.00132	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	7.6e-05	0.0013	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.48e-05	0.00128	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.37e-05	0.00126	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.37e-05	0.00126	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.36e-05	0.00126	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.35e-05	0.00125	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.27e-05	0.00124	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.26e-05	0.00124	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.25e-05	0.00124	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.25e-05	0.00124	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.25e-05	0.00124	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.21e-05	0.00123	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.16e-05	0.00122	CbGpPWpGaD
Phentolamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	7.07e-05	0.00121	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.79e-05	0.00116	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.74e-05	0.00115	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.69e-05	0.00114	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.68e-05	0.00114	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.65e-05	0.00113	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.64e-05	0.00113	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.63e-05	0.00113	CbGpPWpGaD
Phentolamine—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	6.59e-05	0.00112	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.58e-05	0.00112	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.55e-05	0.00112	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.54e-05	0.00111	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.44e-05	0.0011	CbGpPWpGaD
Phentolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.28e-05	0.00107	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.25e-05	0.00107	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.25e-05	0.00107	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.2e-05	0.00106	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	6.17e-05	0.00105	CbGpPWpGaD
Phentolamine—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	6.16e-05	0.00105	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.12e-05	0.00104	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.1e-05	0.00104	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.07e-05	0.00104	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.02e-05	0.00103	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6e-05	0.00102	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.98e-05	0.00102	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.94e-05	0.00101	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.89e-05	0.001	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.85e-05	0.000997	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.65e-05	0.000963	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.65e-05	0.000963	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.61e-05	0.000956	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.52e-05	0.000941	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.52e-05	0.000941	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.47e-05	0.000933	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.43e-05	0.000927	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.42e-05	0.000925	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.35e-05	0.000912	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.27e-05	0.000899	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.27e-05	0.000899	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.19e-05	0.000885	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.19e-05	0.000885	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.04e-05	0.000859	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	5e-05	0.000853	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.97e-05	0.000847	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.9e-05	0.000836	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.76e-05	0.000811	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.69e-05	0.000799	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.62e-05	0.000787	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.61e-05	0.000786	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.61e-05	0.000786	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.56e-05	0.000777	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.3e-05	0.000732	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.29e-05	0.000731	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.28e-05	0.00073	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.28e-05	0.00073	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.23e-05	0.000721	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.19e-05	0.000715	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.17e-05	0.000711	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.01e-05	0.000684	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.95e-05	0.000674	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.95e-05	0.000673	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.89e-05	0.000664	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.89e-05	0.000663	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.87e-05	0.00066	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.83e-05	0.000653	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.78e-05	0.000645	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.61e-05	0.000616	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.56e-05	0.000607	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.54e-05	0.000603	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.51e-05	0.000598	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.48e-05	0.000593	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.45e-05	0.000589	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.4e-05	0.00058	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.26e-05	0.000556	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.21e-05	0.000547	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.16e-05	0.000539	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.16e-05	0.000539	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.09e-05	0.000527	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	3.08e-05	0.000525	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.94e-05	0.000501	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.87e-05	0.00049	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	2.5e-05	0.000427	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.48e-05	0.000422	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.46e-05	0.00042	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.24e-05	0.000381	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.22e-05	0.000379	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.09e-05	0.000356	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.08e-05	0.000354	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.06e-05	0.00035	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.05e-05	0.000349	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.83e-05	0.000311	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.82e-05	0.00031	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.7e-05	0.000289	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.69e-05	0.000288	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.46e-05	0.000248	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000224	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.23e-05	0.000209	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000206	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000183	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.97e-06	0.00017	CbGpPWpGaD
